Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ann Surg Oncol. 2022 Oct;29(10):6381-6392. doi: 10.1245/s10434-022-12144-5. Epub 2022 Jul 14.
Inflammatory breast cancer (IBC) is a rare and aggressive subtype of breast cancer characterized by rapid progression and early metastasis, often with advanced nodal locations, including the supraclavicular (SCV) nodal basin. Previously considered M1 disease, ipsilateral clinical supraclavicular node involvement (N3c) disease is now considered locally advanced disease and warrants treatment with intent to cure. The objective of this study was to evaluate the long-term outcomes of patients with IBC and N3c disease.
This study was conducted using a prospectively collected database of all patients with IBC treated at a dedicated cancer center from 2007 to 2019. Surgical patients with SCV nodal involvement and complete follow-up were identified. Our primary outcome was 5-year overall survival (OS). Multivariate Cox proportional hazards models were used to determine predictors for survival. Event-free survival (EFS) and OS were calculated using the Kaplan-Meier method.
There were 70 patients who met inclusion criteria. All patients underwent comprehensive trimodality therapy. The majority of patients had complete (66.2%) radiologic response in the SCV nodal basins following neoadjuvant therapy. Six patients (8.6%) had a locoregional recurrence, with two (2.9%) occurring in the supraclavicular fossa. The 5-year OS was 60.2% [95% confidence interval (CI) 47.7-72.7%]. Increasing age (hazard ratio 2.7; p = 0.03) and triple-negative subtype (hazard ratio 4.9; p = 0.03) were associated with poor OS. The 5-year EFS was 56.1% (95% CI 40.9-68.8%). The presence of more than ten positive axillary nodes on final surgical pathology (hazard ratio 5.5; p = 0.01) predicted poor EFS.
With comprehensive trimodality therapy and multidisciplinary team approach, patients with IBC with supraclavicular nodal involvement experience excellent locoregional control and favorable survival.
炎性乳腺癌(IBC)是一种罕见且侵袭性的乳腺癌亚型,其特征为快速进展和早期转移,常伴有晚期淋巴结转移,包括锁骨上(SCV)淋巴结区域。既往认为是 M1 期疾病,同侧临床锁骨上淋巴结受累(N3c)现在被认为是局部晚期疾病,需要治愈为目的进行治疗。本研究旨在评估 IBC 伴 N3c 疾病患者的长期预后。
本研究使用了 2007 年至 2019 年在一家专门癌症中心治疗的所有 IBC 患者的前瞻性收集数据库进行。确定了有 SCV 淋巴结受累和完整随访的手术患者。我们的主要结局是 5 年总生存率(OS)。多变量 Cox 比例风险模型用于确定生存预测因素。使用 Kaplan-Meier 方法计算无事件生存(EFS)和 OS。
共有 70 名符合纳入标准的患者。所有患者均接受了全面的三联疗法。大多数患者在新辅助治疗后 SCV 淋巴结区域的放射学反应完全缓解(66.2%)。6 名患者(8.6%)出现局部区域复发,其中 2 名(2.9%)发生在锁骨上窝。5 年 OS 为 60.2%(95%CI 47.7-72.7%)。年龄增长(风险比 2.7;p = 0.03)和三阴性亚型(风险比 4.9;p = 0.03)与较差的 OS 相关。5 年 EFS 为 56.1%(95%CI 40.9-68.8%)。最终手术病理中阳性腋窝淋巴结超过 10 个(风险比 5.5;p = 0.01)与 EFS 不良相关。
通过全面的三联疗法和多学科团队方法,伴锁骨上淋巴结受累的 IBC 患者可获得优异的局部区域控制和良好的生存。